Xia LZ, Liu Y, Xu XZ, Jiang PC, Ma G, Bu XF, Zhang YJ, Yu F, Xu KS, Li H. Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer susceptibility. World J Gastroenterol 2014; 20(32): 11429-11438 [PMID: 25170232 DOI: 10.3748/wjg.v20.i32.11429]
Corresponding Author of This Article
Hua Li, MD, Department of General Surgery, Affiliated People’s Hospital, Jiangsu University, No. 8, Dianli Road, Zhenjiang 212002, Jiangsu Province, China. drlihua212@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Table 4 Comparisons of MTHFR C677T and A1298C polymorphisms for whole and stratified analysis
n
Case/control
OR (95%CI)
P
PHeterogeneity
OR (95%CI)
P
PHeterogeneity
OR (95%CI)
P
PHeterogeneity
OR (95%CI)
P
PHeterogeneity
(TT + CT)/CC
T/C
TT/CC
TT/(CT + CC)
C677T
Total
24
6266/8250
1.23 (1.08, 1.40)
0.002
< 0.0001
1.15 (1.06, 1.25)
0.001
0.0004
1.37 (1.15, 1.63)
0.0005
0.0005
1.17 (1.07, 1.28)
0.0008
0.01
Eastern
16
4716/5839
1.26 (1.08, 1.47)
0.003
0.002
1.21 (1.08, 1.34)
0.0005
0.002
1.42 (1.15, 1.76)
0.001
0.005
1.22 (1.09, 1.35)
0.0003
0.03
Western
8
1550/2411
1.20 (0.92, 1.56)
0.180
0.002
1.05 (0.91, 1.21)
0.53
0.05
1.28 (0.91, 1.82)
0.16
0.009
1.05 (0.88, 1.25)
0.55
0.11
Tumor site
Cardia
Total
10
1043/2941
1.09 (0.81, 1.48)
0.560
0.0005
1.16 (0.95, 1.41)
0.14
0.002
1.28 (0.85, 1.95)
0.24
0.003
1.38 (1.15, 1.67)
0.0006
0.05
Eastern
7
854/2416
1.16 (0.89, 1.52)
0.280
0.05
1.24 (1.04, 1.48)
0.02
0.06
1.57(1.23, 2.00)
0.0003
0.16
1.53 (1.25, 1.87)
< 0.0001
0.31
Western
3
189/525
1.09 (0.38, 3.12)
0.870
0.001
1.00 (0.52, 1.91)
1.00
0.004
0.78 (0.15, 4.16)
0.77
0.003
0.73 (0.27, 1.99)
0.54
0.07
Non-cardia
Total
8
1008/1794
1.38 (1.18, 1.63)
< 0.0001
0.42
1.24 (1.10, 1.40)
0.0003
0.42
1.44 (1.09, 1.91)
0.01
0.31
1.19 (0.93, 1.52)
0.16
0.61
Eastern
5
600/1269
1.35 (1.10, 1.66)
0.004
0.99
1.21 (1.04, 1.41)
0.01
0.87
1.30 (0.87, 1.95)
0.20
0.48
1.10 (0.79, 1.55)
0.57
0.44
Western
3
408/525
1.41 (0.83, 2.38)
0.400
0.03
1.26 (0.91, 1.76)
0.16
0.06
1.55 (0.86, 2.78)
0.14
0.12
1.29 (0.91, 1.83)
0.16
0.53
Lauren’s classification
Intestinal
Total
4
374/1504
1.46 (0.86, 2.47)
0.160
0.05
1.33 (0.97, 1.84)
0.08
0.10
1.88 (1.22, 2.89)
0.004
0.19
1.45 (1.07, 1.95)
0.02
0.76
Eastern
1
142/780
1.25 (0.87,1.87)
0.230
NA
1.25 (0.95, 1.64)
0.12
NA
1.71 (0.90, 3.26)
0.10
NA
1.60 (0.86, 2.97)
0.14
NA
Western
3
232/724
1.61 (0.60,4.29)
0.340
0.03
1.37 (0.74, 2.52)
0.32
0.04
2.01 (1.13, 3.59)
0.02
0.07
1.41 (1.00, 1.98)
0.05
0.58
Diffuse
Total
4
340/1504
1.31 (0.66,2.58)
0.440
0.03
1.19 (0.78, 1.82)
0.42
0.06
1.46 (0.66, 3.21)
0.35
0.13
0.94 (0.56, 1.58)
0.82
0.09
Eastern
1
80/780
1.24 (0.78,1.96)
0.360
NA
1.21 (0.85, 1.73)
0.29
NA
1.51 (0.64, 3.57)
0.34
NA
1.40 (0.61, 3.20)
0.80
NA
Western
3
260/724
1.33 (0.35,5.01)
0.670
0.008
1.14 (0.50, 2.60)
0.76
0.02
1.31 (0.29, 5.83)
0.72
0.04
0.85 (0.46, 1.55)
0.59
0.1
A1298C
(CC + AC)/AA
C/A
CC/AA
CC/(AC + AA)
Total
11
2007/3679
0.98 (0.79, 1.21)
0.840
0.008
0.97 (0.83, 1.14)
0.73
0.03
0.95 (0.71, 1.28)
0.76
0.60
0.95 (0.72, 1.27)
0.75
0.78
Eastern
7
1015/1452
0.96 (0.72, 1.29)
0.790
0.02
0.93 (0.73, 1.19)
0.56
0.04
0.44 (0.21, 0.93)
0.03
0.84
0.46 (0.22, 0.96)
0.04
0
Western
4
702/1408
1.00 (0.71, 1.41)
0.990
0.04
1.07 (0.93, 1.23)
0.36
0.15
1.13 (0.82, 1.57)
0.46
0.69
1.11 (0.81, 1.51)
0.53
0.98
Tumor site
Cardia
Total
2
111/267
0.80 (0.37, 1.74)
0.240
0.13
0.83 (0.41, 1.69)
0.61
0.10
0.76 (0.21, 2.83)
0.69
0.28
0.80 (0.22, 2.93)
0.73
0.36
Eastern
2
111/267
0.80 (0.37, 1.74)
0.240
0.13
0.83 (0.41, 1.69)
0.61
0.10
0.76 (0.21, 2.83)
0.69
0.28
0.80 (0.22, 2.93)
0.73
0.36
Western
0
0
NA
NA
NA
NA
Non-cardia
Total
3
236/301
0.98 (0.69, 1.41)
0.930
0.59
0.93 (0.68, 1.26)
0.62
0.69
0.45 (0.15, 1.40)
0.17
0.86
0.46 (0.15, 1.40)
0.17
0.82
Eastern
3
236/301
0.98 (0.69, 1.41)
0.930
0.59
0.93 (0.68, 1.26)
0.62
0.69
0.45 (0.15, 1.40)
0.17
0.86
0.46 (0.15, 1.40)
0.17
0.82
Western
0
0
NA
NA
NA
NA
Table 5 Comparisons of MTHFR C677T and A1298C polymorphisms for gastric cardia and non-cardia cancers, intestinal-type and diffuse-type gastric cancers
n
Case/control
OR (95%CI)
P
PHeterogeneity
OR (95%CI)
P
PHeterogeneity
OR (95%CI)
P
PHeterogeneity
OR (95%CI)
P
PHeterogeneity
C677T
(TT + CT)/CC
T/C
TT/CC
TT/(CT + CC)
Cardia and non-cardia
Total
7
607/970
0.74 (0.51, 1.08)
0.12
0.01
0.80 (0.59, 1.09)
0.2
0.002
0.82 (0.49, 1.38)
0.46
0.01
0.71 (0.36, 1.39)
0.31
0.06
Eastern
4
418/562
0.76 (0.47, 1.21)
0.24
0.04
0.85 (0.56, 1.27)
0.4
0.01
1.04 (0.52, 2.06)
0.91
0.05
0.89 (0.39, 2.03)
0.78
0.10
Western
3
189/408
0.75 (0.35, 1.61)
0.46
0.04
0.73 (0.45, 1.20)
0.2
0.05
0.59 (0.35, 1.00)
0.05
0.08
0.52 (0.17, 1.59)
0.25
0.26
Intestinal-type and diffuse-type
Total
4
374/340
1.09 (0.74, 1.62)
0.67
0.76
1.10 (0.84, 1.45)
0.5
0.78
1.60 (1.09, 2.35)
0.02
0.87
1.24 (0.68, 2.27)
0.48
0.50
Eastern
1
142/80
1.01 (0.58, 1.74)
0.98
NA
1.03 (0.68, 1.57)
0.9
NA
1.14 (0.44, 2.95)
0.79
NA
1.13 (0.42, 3.04)
0.81
NA
Western
3
232/260
1.19 (0.68, 2.09)
0.55
0.54
1.16 (0.81, 1.66)
0.4
0.57
1.71 (1.13, 2.59)
0.01
0.64
1.32 (0.62, 2.80)
0.48
0.41
A1298C
(CC + AC)/AA
C/A
CC/AA
CC/(AC + AA)
Cardia and non-cardia
Total
2
111/198
0.83 (0.26, 2.64)
0.75
0.03
0.90 (0.34, 2.34)
0.8
0.03
1.87 (0.39, 9.03)
0.44
0.59
1.85 (0.39, 8.69)
0.43
0.75
Eastern
2
111/199
0.83 (0.26, 2.64)
0.75
0.03
0.90 (0.34, 2.34)
0.8
0.03
1.87 (0.39, 9.03)
0.44
0.59
1.85 (0.39, 8.69)
0.43
0.75
Western
0
0
NA
NA
NA
NA
Citation: Xia LZ, Liu Y, Xu XZ, Jiang PC, Ma G, Bu XF, Zhang YJ, Yu F, Xu KS, Li H. Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer susceptibility. World J Gastroenterol 2014; 20(32): 11429-11438